SLXN SILEXION THERAPEUTICS CORP

Silexion Therapeutics to Present at the Upcoming 27th Annual H.C. Wainwright Global Investment Conference

Silexion Therapeutics to Present at the Upcoming 27th Annual H.C. Wainwright Global Investment Conference

Grand Cayman, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced that senior management will be presenting at the upcoming 27th Annual H.C. Wainwright Global Investment Conference taking place on September 8-10, 2025, at the Lotte New York Palace Hotel, New York City.

Silexion's company presentation will take place on Tuesday, September 10, 2025, at 2:00 PM ET. An updated company presentation has been posted to Silexion's website in the Presentation & Events section of the Company’s investor site.

The Silexion management team will be available for in-person one-on-one investor meetings during this event. Investors attending the event may request a one-on-one meeting with Silexion through their H.C. Wainwright representative or e-mail



About Silexion Therapeutics

Silexion Therapeutics is a pioneering clinical stage, oncology-focused biotechnology company dedicated to the development of innovative treatments for unsatisfactorily treated solid tumor cancers which have the mutated KRAS oncogene, generally considered to be the most common oncogenic gene driver in human cancers. The company conducted a Phase 2a clinical trial in its first-generation product which showed a positive trend in comparison to the control of chemotherapy alone. Silexion is committed to pushing the boundaries of therapeutic advancements in the field of oncology, and further developing its lead product candidate for locally advanced pancreatic cancer.



Contacts

Company Contact:

Silexion Therapeutics Corp

Ms. Mirit Horenshtein Hadar, CFO

Capital Markets & IR Contact:

Arx Capital Markets

North American Equities Desk



EN
02/09/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on SILEXION THERAPEUTICS CORP

 PRESS RELEASE

Silexion Therapeutics Announces Selection of Contract Research Organiz...

Silexion Therapeutics Announces Selection of Contract Research Organization to Support Upcoming Phase 2/3 Clinical Trials for SIL204 Strategic CRO to Support Path to Phase 2/3 Trials Following Recently Demonstrated Groundbreaking 97% Inhibition Rates for SIL204 Phase 2/3 Clinical Trials Expected to Commence in First Half of 2026 Following Q4 2025 and Q1 2026 Regulatory Submissions CRO Brings Over 28 Years of Drug Development Experience and Proven Phase 3 Oncology Trial Expertise to Support Upcoming Trial GRAND CAYMAN, Cayman Islands, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Silexion Therape...

 PRESS RELEASE

Silexion Therapeutics to Present at the Upcoming 27th Annual H.C. Wain...

Silexion Therapeutics to Present at the Upcoming 27th Annual H.C. Wainwright Global Investment Conference Grand Cayman, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced that senior management will be presenting at the upcoming 27th Annual H.C. Wainwright Global Investment Conference taking place on September 8-10, 2025, at the Lotte New York Palace Hotel, New York City. Silexion's company presentation will...

 PRESS RELEASE

Silexion Therapeutics Reports Second Quarter 2025 Financial Results an...

Silexion Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update Continued advancement of SIL204 preclinical program with strong efficacy data across multiple KRAS-driven cancer types; company strengthened financial position and maintains progress toward clinical trials GRAND CAYMAN, Cayman Islands, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company developing RNA interference (RNAi) therapies for KRAS-driven cancers, today reported its financial results for th...

 PRESS RELEASE

Silexion Therapeutics Announces Exercise of Warrants for $1.8 Million ...

Silexion Therapeutics Announces Exercise of Warrants for $1.8 Million Gross Proceeds Cayman Islands, July 31, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotech company developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 152,106 of the Company’s ordinary shares originally issued in January 2025 at a reduced exercise price of $11.57 per share. ...

 PRESS RELEASE

Silexion Therapeutics Announces New Preclinical Data Showing Up to 97%...

Silexion Therapeutics Announces New Preclinical Data Showing Up to 97% Inhibition of Cancer Cell Growth, Including New Evidence Against New Previously Untested KRAS Mutation New Results Reveal Unprecedented Inhibition Rates and First Evidence of SIL204's Efficacy Against Previously Untested KRAS Q61H Mutation in Human Cancer Cells, Significantly Expanding its Pan-KRAS Potential; Company on track for the initiation of a Phase 2/3 clinical trial in Q2 2026 Grand Cayman, July 31, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-s...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch